• Samsung Biologics’ largest shareholders’ combined stake slipped to 34,391,646 shares, or 74.29%, as of Oct. 6.
• Holding fell by 1,492 shares from the prior filing on Sept. 7, when the group owned 34,393,138 shares, or 74.30%.
• Samsung Life Insurance’s special account trimmed its stake to 8,902 shares, mainly via on-market sales between Sept. 7 and Oct. 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006800676), on October 06, 2026, and is solely responsible for the information contained therein.